A signal finding study of AEVI-001 in Pediatric Generalized Anxiety Disorder (PGAD).
Phase of Trial: Phase II
Latest Information Update: 15 Mar 2017
Price : $35 *
At a glance
- Drugs Fasoracetam (Primary)
- Indications Generalised anxiety disorder
- Focus Therapeutic Use
- 15 Mar 2017 New trial record
- 09 Mar 2017 According to an Aevi Genomic Medicine media release, company expects to have initial open-label responder data in 2H of 2017.